- Global Pharma News & Resources

Global Anti-obesity Drugs Market 2021-2025 - Limited Number of Approved Drugs and Use of Bariatric Surgery Limited for Morbid Obesity to Drive Growth -

DUBLIN--(BUSINESS WIRE)--The "Global Anti-obesity Drugs Market 2021-2025" report has been added to's offering.

Global Anti-obesity Drugs Market 2021-2025

The anti-obesity drugs market is poised to grow by $ 454.51 mn during 2021-2025 decelerate at a CAGR of 5% during the forecast period.

The market is driven by the limited number of approved drugs and use of bariatric surgery limited for morbid obesity.

The reports on anti-obesity drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors. The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The anti-obesity drugs market analysis includes type segment and geographical landscapes.

This study identifies the growing obese population as one of the prime reasons driving the anti-obesity drugs market growth during the next few years.

The publisher's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading anti-obesity drugs market vendors that include Bausch Health Companies Inc., Currax Pharmaceuticals LLC, F. Hoffmann-La Roche Ltd., Gelesis Inc., GlaxoSmithKline Plc, Novo Nordisk AS, RECORDATI S.p.A., Rhythm Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd., and VIVUS Inc..

Also, the anti-obesity drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Key Topics Covered:

Executive Summary

  • Market Overview

Market Landscape

  • Market ecosystem
  • Market characteristics
  • Value chain analysis

Market Sizing

  • Market definition
  • Market segment analysis
  • Market size 2020
  • Market outlook: Forecast for 2020 - 2025

Five Forces Analysis

  • Five Forces Summary
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

Market Segmentation by Type

  • Market segments
  • Comparison by Type
  • Class III anti-obesity drugs - Market size and forecast 2020-2025
  • Class II anti-obesity drugs - Market size and forecast 2020-2025
  • Class I anti-obesity drugs - Market size and forecast 2020-2025
  • Market opportunity by Type

Market segmentation by Mechanism of Action

  • Market segments
  • Centrally acting anti-obesity drugs
  • Peripherally acting anti-obesity drugs
  • Other anti-obesity drugs

Customer landscape

Geographic Landscape

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2020-2025
  • Europe - Market size and forecast 2020-2025
  • Asia - Market size and forecast 2020-2025
  • ROW - Market size and forecast 2020-2025
  • Key leading countries
  • Market opportunity by geography
  • Market drivers
  • Market challenges
  • Market trends

Vendor Landscape

  • Overview
  • Landscape disruption

Vendor Analysis

  • Vendors covered
  • Market positioning of vendors
  • Bausch Health Companies Inc.
  • Currax Pharmaceuticals LLC
  • F. Hoffmann-La Roche Ltd.
  • Gelesis Inc.
  • GlaxoSmithKline Plc
  • Novo Nordisk AS
  • Teva Pharmaceutical Industries Ltd.
  • VIVUS Inc.


For more information about this report visit

Laura Wood, Senior Press Manager

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Editor Details

  • Company:
    • Businesswire
Last Updated: 13-Apr-2021